Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase
about
A generic system for the expression and purification of soluble and stable influenza neuraminidaseEntry of parainfluenza virus into cells as a target for interrupting childhood respiratory diseaseInfluenza treatment and prophylaxis with neuraminidase inhibitors: a reviewAnalysis of inhibitor binding in influenza virus neuraminidaseStructural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B VirusesStructural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virusStructural and Functional Analysis of Laninamivir and its Octanoate Prodrug Reveals Group Specific Mechanisms for Influenza NA InhibitionCrystal structure of a new benzoic acid inhibitor of influenza neuraminidase bound with a new tilt induced by overpacking subsite C6Functional and Structural Analysis of Influenza Virus Neuraminidase N3 Offers Further Insight into the Mechanisms of Oseltamivir ResistanceCharacterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza virusesInfluenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitorsMechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activityApplication of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDockInfluenza neuraminidase inhibitors: antiviral action and mechanisms of resistanceComparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferonPermeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatmentI222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) virusesResistance mutation R292K is induced in influenza A(H6N2) virus by exposure of infected mallards to low levels of oseltamivirUnique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.The binding properties of the H5N1 influenza virus neuraminidase as inferred from molecular modeling.Computer-based de novo designs of tripeptides as novel neuraminidase inhibitors.In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivir.In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.Recent advances in neuraminidase inhibitor development as anti-influenza drugs.Insight into the oseltamivir resistance R292K mutation in H5N1 influenza virus: a molecular docking and molecular dynamics approach.Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.A method for computational combinatorial peptide design of inhibitors of Ras protein.Combining crystallographic information and an aspherical-atom data bank in the evaluation of the electrostatic interaction energy in an enzyme-substrate complex: influenza neuraminidase inhibitionApproaches and strategies for the treatment of influenza virus infections.Reduced sensitivity of influenza A (H5N1) to oseltamivirToward the design of mutation-resistant enzyme inhibitors: further evaluation of the substrate envelope hypothesis.Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza virusesInfluenza hemagglutinin and neuraminidase membrane glycoproteinsImportance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza virusesStructural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289KTowards a better understanding of the novel avian-origin H7N9 influenza A virus in ChinaCharacteristics of human infection with avian influenza viruses and development of new antiviral agents.Winning the arms race by improving drug discovery against mutating targets.
P2860
Q21091069-4CBBF116-E11D-460E-BC3F-DD60987E31E7Q24530163-BFF54975-F84A-42E8-B83E-068841C4F21AQ26860032-6ED9F98B-3BF6-499D-B6A0-DE61D53E6F0CQ27630835-188354C7-2EBB-4109-92E0-99B80754D4B7Q27663966-8630C590-87A2-4732-B073-D55D97209DEDQ27673631-E118D883-A6E0-4348-A38A-75E5E7D4A391Q27675230-4EFF197F-F960-4C35-9880-812F9A89A6F7Q27678898-1BEB4000-AFC6-458B-9446-867EBDE73074Q27678914-487AC3FB-B9C0-474A-9698-11A57FC70CBFQ27680477-99367F56-122C-462A-B786-12745384A5A5Q27684045-A5C37110-D04D-4B98-B54D-3552F86FB586Q27684054-B9B258A3-4CC3-42CB-B9C1-A1BBB2F3444BQ27702054-F72BC888-73E1-4A52-9724-C24A860F3BDFQ28282405-84F273CF-2664-4D79-BE83-1B0A9DEB8018Q28364114-B6B00AB5-D3C7-46A4-9C73-E8CF8F25D98EQ28483298-4DA6858E-22AE-4F54-B975-1A32B4B21C9CQ28486267-90893103-5A9B-4F64-9DD0-3900A81F5A21Q28533778-32206467-9FAC-490C-A995-09BDDC15E2A1Q28535274-0977C6C3-8FFF-4CD0-A2AC-36A9D15CA813Q30202859-620A26B5-8A93-4350-BB6D-1141CA306D2FQ30356532-EE2160FB-F9B0-4B83-B8F0-594F0BB6478AQ30393867-71B0B09D-F4C0-45CB-BEC5-54484E58E35CQ30403144-76934167-437D-47AD-A83D-14593C549226Q30413844-E1D7482E-3877-4870-94B8-F42B5D5A4A2CQ30416440-F4CDF89F-C0DF-43AC-AC84-3BD07C18A1B3Q30419301-9F3B559A-2858-4289-889A-CCE9A12E25E9Q30432293-F1FB8EDC-E52E-49A3-9871-06390B88F496Q30445738-047A7E6B-B060-41D1-A84A-8571C0E08480Q30725877-75721DEE-FFDA-47C0-9EB6-7E8D6B4CD27AQ33434347-C9CC57BC-1B5D-4F1D-B0A6-33D033B6D271Q33730165-8DFEF799-8C6B-44DE-8F78-B5B23B698217Q33800864-F0DD09D4-9BD7-4241-8CB2-083CC2B3D0B9Q33815097-91E9E814-30D4-414F-9F67-92B1254E70BEQ33999885-CBE03677-12D5-4132-8EFC-F8E28D2CD61DQ34121109-07A94CC2-8559-41B9-9D9A-BDA80032E7AAQ35024169-61F837DE-A5CF-4F20-8D3A-8AB4CA58C40AQ35101694-CE271F88-B2D5-44D6-84E0-FA9241965D2BQ37054816-26C9FEB2-CE00-4399-85EF-6B2FDCC71778Q37217863-B581D216-59C7-4315-A13F-7237B62ECFD3Q37952291-4A7DA885-A026-4FAE-9667-59415BF45F0D
P2860
Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Drug design against a shifting ...... influenza virus neuraminidase
@ast
Drug design against a shifting ...... influenza virus neuraminidase
@en
Drug design against a shifting ...... influenza virus neuraminidase
@nl
type
label
Drug design against a shifting ...... influenza virus neuraminidase
@ast
Drug design against a shifting ...... influenza virus neuraminidase
@en
Drug design against a shifting ...... influenza virus neuraminidase
@nl
prefLabel
Drug design against a shifting ...... influenza virus neuraminidase
@ast
Drug design against a shifting ...... influenza virus neuraminidase
@en
Drug design against a shifting ...... influenza virus neuraminidase
@nl
P2093
P1433
P1476
Drug design against a shifting ...... influenza virus neuraminidase
@en
P2093
A Sahasrabudhe
J L McKimm-Breschkin
J N Varghese
P M Colman
S L Sollis
P304
P356
10.1016/S0969-2126(98)00075-6
P577
1998-06-15T00:00:00Z